1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 19, 2003, Pages 3155-3159

  Alanine, Alexander ^a   Bourson, Anne ^a   Büttelmann, Bernd ^a   Gill, Ramanjit ^a   Heitz, Marie Paule ^a   Mutel, Vincent ^a   Pinard, Emmanuel ^a   Trube, Gerhard ^a   Wyler, René ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(1 BENZYLOXY 4,5 DIHYDRO 1H IMIDAZOL 2 YL)BUTYLAMINE; IMIDAZOLINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VIVO STUDY; STRUCTURE ACTIVITY RELATION;

EID: 0041330444     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00713-3     Document Type: Article

References (32)

1. Kemp J.A., Kew J.N.C., Gill R. Jonas P., Monyer H. Handb. Exp. Pharmacol., Vol. 141. 1999;495-527 Springer-Verlag, Berlin.
2. Gill R., Kemp J.A., Richards J.G., Kew J.N.C. Curr. Opin. Cardiovasc., Pulm. Renal Invest. Drugs. 1:1999;576.
3. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnahev N., Sakmann B., Seeburg P.H. Science. 256:1992;1217.
4. Moriyoshi K.M., Masu M., Ishii T., Shigemoto R., Mizuno N., Nakanishi S. Nature (London). 354:1991;31.
5. Chenard B.L., Menniti F.S. Curr. Pharm. Des. 5:1999;381.
6. Williams K. Mol. Pharmacol. 44:1993;851.
7. Chenard B.L., Bordner J., Butler T.W., Chambers L.K., Collins M.A., De Costa D.L., Ducat M.F., Dumont M.L., Fox C.B., Mena E.E., Meniti F.S., Nielsen J., Pagnozzi M.J., Richter K.E.G., Ronau R.T., Shalaby I.A., Stemple J.Z., White W.F. J. Med. Chem. 38:1995;3138.
8. Fischer G., Mutel V., Trube G., Malherbe P., Kew J.N.C., Mohacsi E., Heitz M.-P., Kemp J.A. J. Pharmacol. Exp. Ther. 283:1997;1285.
9. Pinard E., Alanine A., Bourson A., Büttelmann B., Gill R., Heitz M.-P., Jaeschke G., Mutel V., Trube G., Wyler R. Bioorg. Med. Chem. Lett. 11:2001;2173.
10. Pinard E., Alanine A., Bourson A., Büttelmann B., Heitz M-P., Mutel V., Gill R., Trube G., Wyler R. Bioorg. Med. Chem. Lett. 12:2002;2615.
11. Büttelmann B., Alanine A., Bourson A., Gill R., Heitz M.-P., Mutel V., Trube G., Wyler R. Bioorg. Med. Chem. Lett. 13:2003;829.
12. Curtis N.R., Diggle H.J., Kulagowski J.J., London C., Grimwood S., Hutson P.H., Murray F., Richards P., Macaulay A., Wafford K.A. Bioorg. Med. Chem. Lett. 13:2003;693.
13. Claiborne C.F., McCauley J.A., Libby B.E., Curtis N.R., Diggle H.J., Kulagowski J.J., Michelson S.R., Anderson K.D., Claremon D.A., Freidinger R.M., Bednar R.A., Mosser Scott D., Gaul S.L., Connolly T.M., Condra C.L., Bednar B., Stump G.L., Lynch J.J., Macaulay A., Wafford K.A., Koblan K.S., Liverton N.J. Bioorg. Med. Chem. Lett. 13:2003;697.
14. Shalaby I.A., Chenard B.L., Prochniak M.A., Butler T.W. J. Pharmacol. Exp. Ther. 260:1992;925.
15. Menniti F., Chenard B., Collins M., Ducat M., Shalaby I., White F. Eur. J. Pharmacol. 331:1997;117.
16. Fischer G.; Bourson A.; Kemp J. A.; Lorez H. P.; Neuroscience Annual Meeting, Nov. 16-21, 1996, Washington D.C., USA.
17. Boyce S., Wyatt A., Webb J.K., O'Donnell R., Mason G., Rigby M., Sirinathsinghji D., Hill R.G., Rupniak N.M. J. Neuropharm. 38:1999;611.
18. Kew J.N.C., Trube G., Kemp J.A. J. Phys. 497.3:1996;761.
19. Taniguchi K., Shinjo K., Mizutani M., Shimada K., Ishikawa O., Menniti F.S., Nagahisa A. Br. J. Pharmacol. 122:1997;809.
20. Wright J.L., Gregory T.F., Boxer P.A., Meltzer L.T., Serpa K.A., Wise L.D. Bioorg. Med. Chem. Lett. 9:1999;2815.
21. Alanine, A.; Burner, S.; Büttelmann, B.; Heitz Neidhart, M.-P.; Jaeschke, G., Pinard, E.; Wyler, R. Eur. Pat. Appl. EP 1088818, 2001; Chem. Abstr. 2001, 134, 280718.
22. Mutel V., Buchy D., Klingelschmidt A., Messer J., Bleuel Z., Kemp J.A. J. Neurochem. 70:1998;2147.
23. E. Cohnen, N-Substituted-2-(arylamino)-2-imidazo-lines, 12pp Pat. Appl. DE 2709720 Chem Abstr. 1978, 90, 6396.
24. H. Ramuz, 2-Iminoimidazoline derivatives, 83pp Pat. Appl. DE 2847766; Chem. Abstr. 1979, 91, 211411.
25. Roach A.G., Doxey J.C., Strachan D.A., Cavero I. J. Pharmacol. Exp. 227:1983;421.
26. Hughes D.L. Org. Prep. Proc. Int. 28:1996;127.
27. Timmermans P.B.M.W.M., Van Zwieten P.A. J. Med. Chem. 20:1977;1636.
28. a and logP Measurement. Sirius Analytical Instruments Ltd., Forest Row, UK, 1993.
29. Administered 30 min. before testing in DBA/2 mice according to; Bourson A., Kapps V., Zwingelstein C., Rudler A., Boess F.G., Sleight A.J. Naunyn-Schmiedebergs Arch. Pharmacol. 356:1997;820.
30. Greengrass P., Bremner R. Eur. J. Pharmacol. 55:1979;323.
31. Uhlen S., Wikberg J.E. Pharmacol. Toxicol. 69:1991;341.
32. Kew J.N.C., Trube G., Kemp J.A. Br. J. Pharmacol. 123:1998;463.